Latest stocks in the news

lululemon athletica's (LULU) recent decline persists despite an optimistic outlook for Q4 that fails to generate enthusiasm. Following an impressive 60% surge in shares during 2023, the athletic apparel retailer is off to a slow start in 2024. Although the company enjoyed a robust holiday shopping season with sales growing by 14-15% year-over-year, the marginal adjustments to its Q4 revenue and earnings per share (EPS) guidance are not eliciting much excitement. Specifically, LULU now anticipates Q4 revenue to be in the range of $3.17-$3.19 billion, a slight increase from the previous estimate of $3.135-$3.170 billion, and EPS of $4.96-$5.00, compared to the prior range of $4.85-$4.93. Notably, LULU's initial revenue and EPS projections fell short of expectations. The revised revenue guidance now aligns closely with analysts' original forecasts, while EPS slightly surpasses the initial predictions. LULU reported that sales trends remained balanced across various channels, categories, and geographies in Q4, with the women's business standing out as a notable performer. In the previous quarter, the women's business witnessed a 19% growth, driven by new product launches, strength in bottoms, and consistent performance in key franchises. Concerns about the uncertain macro environment affecting men's apparel purchases were expressed by LULU in the previous quarter, potentially contributing to a more cautious approach in raising sales guidance. Meanwhile, rival NIKE (NKE) is grappling with the impact of slowing apparel sales, reporting a 4% decline in North American revenue and revising its FY24 revenue growth outlook downward to approximately 1%. Despite challenges in the retail climate, LULU appears to be in a relatively better position than NKE. LULU's brand maintains strong pricing power in a promotional retail environment, leading the company to raise its Q4 non-GAAP gross margin guidance to 58.6-58.7% from 58.3-58.6%. Nevertheless, LULU's conservative guidance increase is posing challenges to justifying its premium valuation, especially with a price-to-earnings (P/E) ratio exceeding 60x.

Crocs (CROX) experiences a significant surge in its stock price following the release of better-than-expected preliminary Q4 results and optimistic revenue guidance for FY24. The footwear company, which also owns the HEYDUDE brand, had faced a nearly 20% decline in its stock value since mid-December but saw a swift rebound on the positive outlook. The footwear industry, influenced by lackluster Q2 results from NIKE (NKE) in November, had a bearish tone, impacting Crocs as well. Despite a challenging November quarter with factors like inflation, higher interest rates, and resumed U.S. student loan payments, Crocs projected Q4 revenues of $903-$938 million, slightly below consensus. Encouragingly, Q3 showed positive trends such as continued market share growth in North America for the Crocs brand, healthy demand, and expanded adjusted gross margins. The Q4 performance surpassed expectations, with Crocs brand revenue growing by approximately 10%, offsetting HEYDUDE's 19% sales decline. Despite a difficult operating environment during the holiday season, effective planning allowed Crocs to surpass its financial targets. Looking ahead to FY24, Crocs anticipates a slower sales growth rate of 3-5%, compared to an 11% increase in FY23, while adjusted operating margins are expected to dip around 2 percentage points to 25%, attributed to investments in brand-related initiatives. Despite ongoing challenges such as elevated promotions, persistent inflation, and consumer preferences for value products, the mid-single-digit revenue growth is commendable, considering the reasonably solid growth expected in 2023. The positive Q4 guidance and the reassuring FY24 revenue forecast bring relief to Crocs, instilling confidence in its ability to navigate obstacles and potentially initiate a broader turnaround.

Abercrombie & Fitch (ANF) stands out in the challenging apparel retail sector, defying industry struggles with strong performance throughout 2023, extending into a successful holiday shopping season. ANF raised its Q4 net sales growth guidance to high-teens, surpassing its earlier projection of low-double-digit growth. The Q4 operating margin outlook was also increased to 15%, up from the previous range of 12-14%, attributed to increased sales leverage and restrained discounted pricing. ANF's notable resurgence in 2023, marked by a 285% surge in its stock price, is mainly attributed to the success of its Abercrombie brand, which achieved a remarkable 26% comp growth in Q3. Although specific Q4 sales figures for Abercrombie and Hollister were not provided, the company highlighted the continued leadership of Abercrombie brands in driving strong Q4 sales growth. The women's business, in particular, experienced record Q4 sales, driven by on-trend product assortments, successful expansion beyond denim in the bottoms business, and strength in the dresses category. ANF's strategic management of a more limited inventory, with a 20% year-over-year decrease at the end of Q3, positioned the company to benefit from higher pricing during the holiday shopping season, avoiding the highly promotional retail environment. Overall, ANF emerged as a clear winner in the apparel retail sector during this holiday season, capitalizing on a clean inventory profile and the growing strength of the Abercrombie brand.

Following an incident over the weekend, Boeing (BA) faces a 7% drop in its stock value as the FAA temporarily grounds specific Boeing 737 MAX 9 jets operated by U.S. airlines. During an Alaska Air (ALK) flight from Portland, OR to Ontario, CA, part of the aircraft, a "plug" where an emergency exit is typically placed on MAX 9 jets with a certain seat limit, detached, leading to the plane's immediate return to Portland International Airport with a safe landing and no injuries. Federal regulations mandate additional emergency doors on planes with at least 180 seats; however, the affected aircraft had fewer than 180 seats, allowing for the use of "plugs" instead of doors. Spirit Aerosystems (SPR), the part supplier responsible for manufacturing the "plug," faces an 8% stock drop as it undergoes scrutiny over the incident. SPR's significant customers include Boeing (53% of consolidated FY22 sales), Airbus (22%), and the U.S. Government (13%). Investors express impatience due to a series of quality control issues at SPR, including a fuselage section problem in certain 737 models in April and improperly drilled holes on the aft pressure bulkhead in August. While Boeing will encounter near-term cost challenges with the reported grounding of 171 MAX 9 jets, representing a small fraction of its total fleet, SPR bears the brunt of the selling pressure, given its track record of quality control issues. U.S. airlines Alaska Air (ALK) and United Airlines (UAL), configuring the MAX 9 without extra emergency exits, are affected to varying degrees, with ALK experiencing the incident, grounding its fleet and canceling over 150 flights. The incident, which adds to SPR's list of setbacks, prompts an investigation, and until further clarity is provided, Boeing is expected to recover quicker than SPR from this setback.

Previous update:

CVS (CVS) Health's positive trajectory persists as it confirms its earnings per share (EPS) guidance for fiscal years 2023 and 2024. Tom Cowhey, previously interim CFO since October, now assumes the permanent role, succeeding Shawn Guertin on leave due to family health reasons. Despite hurdles in the past year, including heightened medical benefit costs impacting the Health Care Benefits segment and sluggish growth in the Pharmacy & Consumer Wellness segment due to diminishing COVID-19 product sales, CVS closed 2023 with a robust 16% rally in December. Reiterating fiscal year 2023 EPS and revenue guidance, CVS now foresees its EPS falling within the upper bracket of the $8.50-$8.70 range. Looking forward to fiscal year 2024, CVS upholds expectations of at least $8.50 EPS and cash flow from operations of a minimum of $12.5 billion. The optimistic forecast stems from a substantial surge in Medicare Advantage (MA) membership, with an anticipated growth of no less than 800,000 members in 2024, surpassing the earlier projection of 600,000. The pivotal factor driving this favorable outlook is the enhancement of CVS's star rating for its Medicare Advantage program. In May of the previous year, CVS had anticipated a potential decline in operating income for 2024 due to diminished plan star ratings. However, recent disclosures reveal that 87% of Aetna Medicare Advantage members will be enrolled in contracts rated at four stars or higher. This has led to CVS attracting new members from competitors such as United Health and Humana, with the company noting an "increased proportion of new sales originating from competitor MA plans." While challenges such as an escalating medical benefit ratio may persist, particularly with the rise in outpatient procedures, the improved star rating and expanding Medicare Advantage membership are anticipated to counter these challenges and contribute to CVS's sustained upward momentum.

Netflix (NFLX) is considering ways to generate additional revenue from its mobile gaming venture, signaling a strategic move beyond its initial foray into the gaming space in November 2021. Despite its relatively short experience compared to industry giants like Electronic Arts (EA) and Take-Two (TTWO), Netflix has been actively expanding its gaming capabilities, acquiring several game development studios and increasing its game offerings from five to over 80 titles. While many games are provided to streaming subscribers through licensing agreements, Netflix is now contemplating introducing in-app purchases or hosting ads in games to extract additional revenue. Currently, all games are accessible to Netflix subscribers at no extra cost. The company's recent success in its streaming business, highlighted by a remarkable addition of +8.76 million global streaming paid net subscribers, has demonstrated its ability to address challenges, such as password sharing crackdowns, and maintain a competitive edge through appealing intellectual property (IP) and content. Netflix's move into monetizing its gaming division aligns with its recognition of the substantial market opportunity in mobile gaming, estimated at approximately $140 billion outside China and Russia, as mentioned by management in late October. Unlike traditional gaming companies like EA and TTWO, Netflix's strength lies in its video content-first approach, leveraging its established fanbase from popular shows like Stranger Things to create mobile games as an extension of its existing content. If the monetization efforts in the gaming sector prove successful, Netflix stands to gain significantly over the long term.

Costco (COST) showcased robust sales performance during the holiday shopping season, positioning itself as a clear winner. In December, the membership warehouse retailer reported a notable surge in comparable sales, excluding fluctuations in gasoline prices and foreign exchange impact, with an impressive 8.1% increase. This outpaced the gains observed in November at 4.4% and October at 3.4%. The retailer's popularity during the festive season was evident as customer traffic recorded a significant 7.5% jump, indicating its ongoing ability to capture market share from competitors, including grocery store chains. Notably, the food and sundries category stood out with a high-single-digit growth, reflecting consumers' inclination towards value-oriented bulk purchases. Costco's positive trend in Q1 results, reported on December 14, hinted at a successful holiday shopping season surpassing expectations. Beyond traditional holiday items, customers displayed increased interest in big-ticket items, resulting in a mid-20% surge in appliance sales. Notable rebounds were also observed in the sales of TVs, jewelry, and electronics, contributing to a 6.3% rise in Q1 eCommerce same store sales. It's worth noting that significant categories like appliances, TVs, jewelry, and electronics collectively constitute a substantial portion, ranging from 50-60%, of Costco's total eCommerce sales. This positive momentum extended into December, where non-food categories experienced a noteworthy high-single-digit increase. Strong performances were particularly evident in jewelry, gift cards, and tires, offsetting softness observed in toys, sporting goods, and seasonal products. Bolstered by this improvement in non-food sales, eCommerce same store sales achieved an impressive 17.4% growth, even though Costco faced a favorable year-over-year comparison of -5.4%. The overall takeaway is that Costco emerged victorious in the holiday shopping season, evident in the stock's 15% gain since mid-November. The strong December sales results align with the positive trajectory highlighted in the Q1 earnings report. Looking ahead, a potential catalyst for the company could be an anticipated membership increase, as indicated by Costco CFO Richard Galanti, marking it as a matter of when, not if.

Constellation Brands (STZ), a producer of beer, wine, and spirits, experienced mixed results in Q3. Although the company fell short of Q3 revenue estimates and adjusted its FY24 Wine and Spirits organic sales outlook downward, the resilience of its Beer segment provided a silver lining. Despite weak performance in Wine and Spirits, the Beer segment, constituting 80% of total revenue, not only offset the decline but also led to a double-digit adjusted earnings beat in Q3, maintaining the company's FY24 adjusted EPS outlook. Total sales saw a modest 1.4% increase year-over-year to $2.47 billion, primarily driven by a 4.0% rise in the net sales of Constellation Brands' Mexican beer brands, including Modelo, Corona, and Pacifico. Beer shipments and depletions recorded a 3.4% and 8.2% year-over-year increase, respectively, continuing an upward trend from previous quarters. The Beer segment outpaced the total beer category and the high-end segment in both dollar sales and volume growth. The strength in Constellation Brands' Beer business positively impacted operating margins, leading to a 100 basis points improvement year-over-year to 38.5%. Wine and Spirits also experienced a modest increase in operating margins, growing by 60 basis points to 25.4%, primarily due to deflation in the supply chain. Despite challenges, Constellation Brands exceeded bottom-line estimates for the fourth consecutive quarter. In contrast, Wine and Spirits faced ongoing demand challenges in Q3, reflecting the strategic shift made nearly three years ago to focus on a premium portfolio. This strategy resulted in a 7.0% organic net sales decline, with shipments and depletions dropping by 11.6% and 10.0%, respectively. Notably, The Prisoner, STZ's largest fine wine brand, achieved a 6.0% depletion growth, outperforming its segment in the broader wine category. In craft spirits, Mi CAMPO tequila, STZ's second-largest brand, experienced over 80% depletion growth. Constellation Brands adjusted its FY24 Wine and Spirits organic net sales forecast considerably, anticipating a 7.0-9.0% decline year-over-year. In contrast, the Beer business is expected to maintain its previous 8-9% net sales growth target in FY24. Despite challenges in Wine and Spirits, the Beer segment supported the company's reiteration of FY24 adjusted earnings guidance of $12.00-$12.20. While the Beer segment remains a stronghold for Constellation Brands, the ongoing struggles in Wine and Spirits present a hurdle for potential stock growth. Until a turnaround occurs in this segment, the company may face limitations in achieving more significant returns each quarter.

Previous update:

In the second quarter (Q2) of the fiscal year, RPM Inc (RPM) faced challenges, experiencing a downturn of 4%. This decline was attributed to weaknesses in the do-it-yourself (DIY) and specialty original equipment manufacturer (OEM) markets, resulting in the company missing both earnings and revenue estimates for the first time in at least a year. Additionally, RPM lowered its sales growth forecast for the fiscal year 2024 (FY24) in May. Despite the setbacks, there were positive aspects stemming from the MAP 2025 savings initiatives implemented by the specialty coatings manufacturer. However, these were overshadowed by persistent softness in the DIY and specialty OEM markets. The headline figures painted a disappointing picture, with RPM falling short of earnings expectations for the first time in six quarters. Year-over-year sales remained flat at $1.79 billion, performing worse than the modest positive growth anticipated by analysts. Notably, RPM's Consumer Group and Specialty Products Group experienced negative sales growth during the quarter, declining by 5.2% to $578.69 million and 16.6% to $176.98 million, respectively. Consumer Group was affected by weak retail performance, as customers redirected their discretionary spending towards travel and entertainment rather than home improvement projects, echoing trends seen at Lowe's and Home Depot. Retailers' cautious inventory management further intensified volume pressure on RPM. Specialty Products Group faced challenges from soft specialty OEM demand, particularly in markets with higher exposure to residential housing. On a more positive note, the Construction Products Group and Performance Coating Group prevented a more significant decline in Q2 sales, achieving growth rates of 8.1% and 5.1%, reaching $661.75 million and $374.86 million, respectively. Both segments benefited from a focus on repair and maintenance, along with robust demand for infrastructure reshoring and high-performance buildings. RPM's management changes and MAP 2025 initiatives yielded positive results, with increased collaboration among sales teams in Africa, the Middle East, and Asia Pacific contributing to growth in these regions. MAP 2025 also led to double-digit adjusted EBIT growth and reiterated FY24 growth in the low double-digit to mid-teen range. However, challenges within the Consumer and Specialty Products segments are expected to persist throughout the year, resulting in a reduced FY24 revenue growth outlook of a low-single-digit percentage, down from mid-single-digits. The relative strength observed in RPM's Construction Products and Performance Coatings segments is encouraging and holds promise for peers PPG Industries and Axalta Coating Systems, both of which have greater exposure to performance and industrial coatings than RPM. Conversely, due to elevated interest rates, existing home turnover has been at a multi-decade low, and until interest rates decrease and homeowners consider moving, RPM's Consumer and Specialty Products segments may continue to face challenges, which could also impact competitor Sherwin-Williams negatively.

Mobileye Global (MBLY), a semiconductor company specializing in Advanced Driver Assistance Systems (ADAS) and self-driving technology, is facing a significant downturn in its FY24 outlook due to an excess inventory issue. While semiconductor companies dealing with PC, laptop, and mobile device markets are recovering from previous inventory challenges, a new supply-demand imbalance is emerging in the automotive end market. MBLY attributes its weak FY24 guidance to excess inventory levels at its customers, impacting the sales of its EyeQ Systems-on-Chip (SoCs). The company anticipates a substantial decline of around 50% year-over-year in revenue for Q1, contrasting sharply with the anticipated 20%+ growth predicted by analysts. This guidance downgrade has led to selling pressure not only for MBLY but also for other chip makers in the automotive sector, such as Ambarella (AMBA), which manufactures computer vision chips for advanced driver-assistance systems. Although Intel (INTC) has reduced its direct exposure to the auto industry following the spin-off of MBLY in 2022, its stock is affected due to an 88% stake in MBLY. INTC's potential use of MBLY holding as a source of capital for facility construction contributes to its weakened stock performance. Despite MBLY's previous strong performance, with nearly 90% gains from its IPO price, the current challenges stem from dwindling demand amid inventory drawdowns among Tier 1 auto OEM customers. EyeQ shipments are projected to decrease to 31-33 million units compared to an estimated 37 million units in 2023. Consequently, MBLY anticipates a 1Q24 adjusted operating loss ranging from ($80)-($65) million, in contrast to the $124 million adjusted operating profit in the year-earlier period. The unexpected severity of the FY24 guidance downgrade is catching market participants off-guard, signaling challenges not only from the ongoing auto industry inventory correction but also potential cautious ordering due to macroeconomic conditions.

Despite Conagra (CAG) reporting Q2 (Nov) results with a modest upside in earnings per share (EPS) and generally in-line revenues, the company is experiencing a pullback of 2.4%. The main concern stems from the lowered EPS and organic revenue guidance for FY24, indicating a weaker second half of the fiscal year than previously anticipated. In the Grocery & Snacks segment, revenue declined by 4.1% to $1.3 billion, attributed to a 0.4% price/mix decrease and a more significant 3.7% volume decrease, primarily due to ongoing lower consumption trends. However, CAG managed to gain dollar share in snacking and staples categories. The Refrigerated & Frozen (R&F) segment faced a more substantial revenue decline of 5.8% to $1.3 billion, with a 2.5% price/mix decrease and a 3.3% volume decrease, reflecting shifts in consumer behavior toward multi-serve meals and scratch cooking. While CAG's smaller International and Foodservice segments showed growth, their contributions are relatively small compared to the primary segments. CAG attributed the challenges to shifts in US consumer behavior starting in spring 2023 due to inflation, causing a reprioritization of food choices. The company expects these trends to be transitory but acknowledges a slower-than-expected return to normal consumer behavior, affecting volumes and mix in Q2. Despite ongoing macro challenges and increased brand investments, CAG highlighted solid margins and EPS delivery in Q2. However, investors are disappointed, as progress in volume recovery has been slower than anticipated, dashing hopes for a meaningful recovery in the second half. The stock had trended lower from early May to October but showed signs of consolidation and slow recovery, setting expectations for a more optimistic Q2 or a bullish outlook for the second half.

Despite Walgreens Boots Alliance (WBA) managing to reverse its trend of two consecutive earnings misses in Q1 (Nov), beating estimates by a low-single digit and reporting accelerated year-over-year sales growth, the company is facing a significant downturn, reflected in a 9% decline in its stock value. Although WBA maintained its FY24 (Aug) earnings target, it announced a substantial 48% reduction in its quarterly dividend, previously boasting a rich 7.5% annual yield. The cut is aimed at freeing up capital for investment in its pharmacy and healthcare businesses under the leadership of the new CEO, Tim Wentworth, who took the helm in late October. Margins continued to compress in Q1, with adjusted gross and operating margins declining by 180 basis points and 110 basis points year-over-year, leading to a 43% year-over-year drop in WBA's bottom line to $0.66 per share. However, the contraction was less severe than analysts anticipated, resulting in WBA's first earnings beat since 2Q23 (Feb). Despite robust top-line growth of 9.9% year-over-year to $36.7 billion, outperforming expectations, the challenging retail landscape is evident in the U.S. Retail Pharmacy segment's underperformance, with just a 6.4% climb on +8.1% comp growth. The retail environment remains weak, as retail comps fell -5.0% in Q1, indicating stressed consumers shifting towards value brands. International sales, however, were a positive standout, increasing by 12.4% year-over-year to $5.83 billion, with Boots UK showing positive comparable pharmacy and retail sales. In the U.S. Healthcare segment, pro forma sales grew by 12.0% year-over-year, led by VillageMD and Shields, and adjusted operating losses narrowed, indicating a path to profitability. WBA reiterated its forecast of reaching adjusted EBITDA breakeven in FY24 (Aug), a $425 million improvement year-over-year. Despite these encouraging developments, the slashed dividend, challenges in the end consumer market, and an unfavorable cold and flu season have dampened initial enthusiasm. WBA remains a risky turnaround play, especially in the current retail environment, and caution is advised ahead of CVS Health's (CVS) Q4 (Dec) report next month.

SentinelOne (S), a cybersecurity company that has been gaining ground in the endpoint protection sector, recently made headlines by announcing its cash-and-stock acquisition of PingSafe, a cloud native application protection platform (CNAPP). Despite the positive momentum behind SentinelOne, particularly with its Singularity Platform challenging CrowdStrike (CRWD), the news resulted in a sell-off of SentinelOne shares. The decline, however, is not only attributed to profit-taking following a substantial 45% surge in December but also to concerns about the dilutive impact of the PingSafe acquisition. While the company has showcased progress in profitability, reducing its Q3 non-GAAP net loss significantly, investors seem uneasy about taking a potential step backward. The lack of specific financial details for the PingSafe deal and the absence of financial data for PingSafe itself contribute to the uncertainty surrounding SentinelOne's future financials. Despite strong recent financial results, including an 11% increase in net new ARR and an eight-percentage point expansion in non-GAAP gross margin, the acquisition is met with skepticism. From a strategic standpoint, SentinelOne sees PingSafe as a fitting addition to enhance its cloud workload security and cloud data security capabilities. This move aligns with the company's strategy of providing a unified security system, eliminating the need for enterprises to integrate multiple-point solutions. SentinelOne's Singularity Platform, known for its AI-powered autonomous threat protection and response capabilities, offers a unified view of incidents and threats across all endpoints and cloud workloads. While this strategy seems promising for creating a best-of-breed cloud security platform in the long term, investors are currently not rewarding SentinelOne, focusing on the potential dilutive impact on earnings in the near term.

Previous update:

DoorDash (DASH) has started 2024 with a modest slowdown, as its shares dip following a report from the Financial Times indicating the food delivery company's plans to extend beyond its primary U.S. restaurant-focused business. In 2023, DoorDash prioritized expanding its offerings beyond U.S. restaurants, domestically and internationally, following its acquisition of the food and merchandise delivery platform Wolt for approximately €7.0 billion in the summer of 2022. Leveraging its strong global presence and diversifying revenue streams, especially given its market leadership in U.S. food delivery, remains advantageous for DoorDash. Beyond the U.S., DoorDash operates in 27 countries, a result of its Wolt partnership. Despite impressive growth across various regions, the company acknowledged a need for improvement, especially compared to its core U.S. market. Consequently, in 2024, DoorDash emphasizes overseas expansion, whether in food delivery or venturing into other channels. The expansion into new verticals played a significant role in DoorDash's stellar performance in 2023. The new categories business, involving deliveries from merchandise vendors, saw sequential acceleration in Q3, with the grocery business alone witnessing a doubling in gross order volume year-over-year. Utilizing its existing network of drivers, DoorDash can swiftly enhance unit economics within its new categories business. Amid the fragmented landscape of the food delivery industry, DoorDash, as a leader, might incorporate mergers and acquisitions (M&A) into its expansion strategy to fortify its market dominance. This approach aims to distance the company from its nearest competitors and preserve its leadership position. Despite the positive momentum, DoorDash anticipates challenges in 2024, primarily arising from cumulative inflationary pressures and the impact of weight-loss drugs. Regarding the latter, the company's management remains uncertain about the drugs' effect, while on the inflation front, DoorDash is experiencing cost-related pressures due to certain regulations like minimum wage increases. Additionally, consumer spending tightening with the resumption of student loan payments and widespread inflation poses demand-side challenges. However, DoorDash believes it has already navigated peak inflation, which exhibited a slower rise in the latter half of 2023. With a turnaround momentum from an exceptional 2023, DoorDash aims to capitalize on its success by deploying capital efficiently and considering potential M&A opportunities.

Previous update:

Jabil (JBL) has maintained a relatively stable position despite revising its Q2 (Feb) guidance downward, and this adjustment appears to be solely attributed to the quicker-than-expected divestiture of its Mobility business. Initially projected to conclude on January 31, the deal has already closed, prompting the guidance modification. The divestiture involved Jabil selling its Mobility business to BYD Electronic for a cash transaction valued at $2.2 billion, as announced on September 26. The expedited completion of the deal enables Jabil to commence plans for reducing stranded costs and initiating an accelerated series of buybacks throughout FY24. Anticipating a full utilization of its $2.5 billion repurchase authorization this fiscal year, Jabil expresses confidence in offsetting lower income in Q2 and achieving core earnings exceeding $9.00 per share for FY24. Strategically, the divestiture aligns with Jabil's focus on higher-growth areas by reducing exposure to the fluctuating and intensely competitive consumer electronics market. With the Mobility business specializing in consumer electronics, this move shields Jabil from the uncertainties associated with discretionary spending in this segment. Despite challenges, Jabil maintains a resilient business, notably in key growth sectors such as electric vehicles (EVs), autonomous driving, artificial intelligence (AI), cloud computing, renewable energy, and healthcare. While acknowledging a broad slowdown in demand across multiple end-markets and subsequent adjustments in demand schedules by customers, Jabil anticipates this slowdown to be temporary. The company still foresees growth in crucial areas like EVs and renewables, albeit at a slightly slower pace than initially expected. Its healthcare business remains robust, and in the cloud sector, Jabil is thriving in the AI data center space. However, the Connected Devices segment has experienced prolonged softening, and this trend is not anticipated to change in the short term. Within the enterprise, communications, and 5G, Jabil acknowledges expectations of continued softness tied to global roll-outs. Renewables, specifically in solar and wind, have observed a decline. Given the mixed landscape of Jabil's end markets, the decision to divest the Mobility segment aligns logically with the prevailing conditions. The challenging macroeconomic environment has led to reduced spending on discretionary items like consumer electronics. Consequently, the divestiture is poised to enhance results over the coming quarters and strengthen Jabil's financial position. The downward revision in guidance is viewed as a non-event, primarily attributed to timing considerations rather than reflecting operational or demand challenges.

NVIDIA (NVDA) is aiming to conclude an exceptional year on a positive note with the recent introduction of a specialized version of its top-tier GeForce RTX 4090 graphics card, named the RTX 4090D, designed specifically for the Chinese market. The move comes as part of NVIDIA's strategy to navigate new U.S. export restrictions on AI chips to China by developing products that align with revised computing thresholds. This launch falls within the expected timeframe outlined by management for the first quarter of 2024. Given that approximately a fifth of NVIDIA's total revenue is derived from China, the ability to cater to this region is crucial. The competitive landscape is intensifying, particularly with China's Huawei making strides in developing its own AI chips, occasionally surpassing NVIDIA's offerings. During the October quarter earnings call in November, NVIDIA had already hinted at the forthcoming availability of China-focused chips designed to comply with U.S. export regulations. The company acknowledged that these products were unlikely to significantly impact Q4 (Jan) revenue. As a result, market attention is now focused on NVIDIA's other products, particularly those based on its Hopper architecture. The Hopper architecture, specifically designed for data centers, features the H100 product, priced at approximately $40,000 in contrast to the $2,000 range for the 4090, boasting substantial performance enhancements over the highest-end RTX card. NVIDIA's latest Hopper-based cards are in full production and are expected to contribute to a new multibillion-dollar product line in 2024, catering to customers aiming to establish an AI factory. Notably, due to export restrictions on lucrative AI-focused products to countries like China, Vietnam, and specific nations in the Middle East, NVIDIA anticipates a significant decline in sales to these regions in Q4. While the introduction of the slower-spec 4090 GPU in China is a positive development, investors are eagerly awaiting updates on other NVIDIA products, particularly those based on the Hopper architecture. NVIDIA is actively working with affected customers to pursue U.S. licenses, although the outcome and potential revenue impact remain uncertain. The company acknowledges the possibility of disruptions but anticipates compensating for the slowdown through heightened demand in other regions in the short term. However, persistent delays could lead to more substantial revenue disruptions in subsequent quarters of 2024. NVIDIA's management emphasizes the importance of global investments in AI infrastructure for economic growth and industrial innovation. If China faces challenges in acquiring the latest AI-powered GPUs from NVIDIA, it may turn to domestic competitors. With NVIDIA's stock having surged by over 240% this year, the company operates in a territory where minor setbacks could trigger significant profit-taking actions.

Previous update:

Brinker International (EAT) has experienced notable momentum since mid-October, witnessing a 50% surge and recently reaching a new 52-week high. The restaurant operator, known for brands like Chili's and Maggiano's, appears to be on a positive trajectory, and investors are recognizing the potential value in this turnaround. In Q1 (September), EAT reported its most substantial earnings per share (EPS) beat in the past three quarters and raised its FY24 EPS guidance significantly to $3.35-3.65 from $3.15-3.55. While same restaurant comps showed strength at +5.8% (Chili's +6.1%; Maggiano's +2.6%), a slight decline in comps from the previous quarters (JunQ: +6.6%; MarQ: +10.8%) was noted. The improvement in comps can be attributed to heightened menu pricing and a favorable item mix. Notably, Chili's has outperformed the casual dining industry for four consecutive quarters, with a narrowing traffic gap compared to the industry in SepQ, despite challenges like discontinuing Maggiano's Italian Classics and cycling through deep discounting on It's Just Wings. EAT attributes this traffic progress to the strengthening core business of Chili's, boosted by intensified marketing efforts. The company, currently in its third wave of advertising since March, has seen positive responses, particularly to its $10.99 platform. EAT believes that advertising superior value is an effective strategy to navigate economic headwinds. Additionally, EAT claims to have consistently gained a share of wallet over the past four quarters across all day parts, especially during dinner, with higher-income households exhibiting the fastest growth. As it progresses into FY24, EAT anticipates sustaining traffic growth ahead of the industry. A noteworthy development for EAT is the relaunch of Chicken Crispers at Chili's. Through recipe simplification, larger piece counts, and pricing adjustments supported by improved sauce and side innovation, EAT reports a decrease in the average crisper food cost as a percentage of sales from 23% to 20%, resulting in a 40% increase in Crispers sales. This strategic move promises a more significant business with reduced food costs and improved margins. The stock's recent movement is likely attributed to multiple factors. EAT's healthy comps, the positive response to advertising efforts emphasizing Chili's value proposition, and perceived affordability have all contributed. Even after its recent rally, EAT maintains a relatively low price-to-earnings (P/E) ratio of 12.5x. Despite reaching the mid-$40 range, the stock remains significantly below its early 2021 levels, suggesting potential room for further recovery.

Tesla (TSLA) is experiencing a relatively neutral market response today following reports suggesting that CEO Elon Musk might announce the launch of Tesla in India as early as January. While Indian individuals could previously import Tesla vehicles at high import fees, sometimes double the car's price, the company did not offer direct purchases through its website or retail facilities. Tesla had refrained from significant investment in India due to high import duties. However, this scenario could change in the coming year as reports indicate that Indian regulators may reduce tariffs on imported automobiles, including electric vehicles, to as low as 15%, benefiting Tesla and its competitors. Elon Musk might also unveil plans for a manufacturing facility in India, potentially near auto OEM giant Tata Motors, which owns well-known brands like Jaguar Land Rover. India, a substantial global automobile market, has relatively low vehicle ownership rates, with around 20 vehicles per 1,000 people. Despite this, the country holds vast potential with tens of millions of potential customers, especially as India's middle class expands, currently representing only a third of the total population. While domestic sales are a possibility, Tesla may primarily view India as an ideal location for exporting vehicles to neighboring nations. Reports of Tesla's entry into the Indian market have surfaced throughout the year. In November, there were discussions about a potential $2.0 billion investment in a regional factory if the government reduced import duties to 15% in the initial two years. However, these talks failed, with recent reports indicating that India would not lower its EV import taxes. In July, Tesla explored plans for producing a low-cost EV priced around $24,000, but no tangible outcomes emerged from those discussions. Given the previous breakdown of discussions, investor skepticism is understandable. However, with 2024 potentially marking the year when Tesla overcomes regulatory challenges in India, the company could see a significant sales boost over the long term.

Previous update:

Cytokinetics (CYTK), a late-stage biopharmaceutical firm specializing in cardiovascular disease treatments, has experienced a significant surge to multi-decade highs following the release of positive data from its SEQUOIA-HCM Phase 3 clinical trial for aficamten. Aficamten, an investigational once-daily pill, is designed to address hypertrophic cardiomyopathy (HCM), a severe heart condition characterized by the thickening of cardiac muscles, resulting in reduced pumping function and limitations in exercise capacity. With approximately 280,000 diagnosed HCM cases in the U.S. and an estimated 400,000-800,000 undiagnosed cases, CYTK is optimistic about aficamten becoming the preferred treatment for physicians and patients based on the promising Phase 3 trial outcomes. The drug exhibited significant enhancement in exercise capacity compared to the placebo, showing increased peak oxygen uptake measured through cardiopulmonary exercise testing (CPET) with a least square mean difference of 1.74 mL/kg/min. Aficamten also demonstrated substantial and clinically meaningful improvements across all ten pre-specified secondary endpoints, maintaining good tolerability. Adverse events occurred in 5.6% and 9.3% of patients on aficamten and placebo, respectively. Looking ahead, CYTK aims to seek FDA approval for aficamten, anticipating the submission in the second half of 2024. Considering the favorable clinical trial data and the existence of a similar drug by Bristol-Myers Squibb (BMY) in the market, the approval prospects seem promising. If approved, aficamten could be a transformative asset for CYTK, marking its first commercially available treatment and potentially evolving into a multi-billion-dollar product, making the company more appealing to potential suitors. Recent reports of takeover interest in Cytokinetics suggest increased attention amid generally slow deal-making, especially within the pharmaceutical and biotech sectors, which have seen heightened M&A activity. The overall implication is that CYTK is poised to transition from a late-stage biopharmaceutical entity to a commercial-stage company, elevating its attractiveness for potential acquirers.

Amazon (AMZN) is venturing into the advertising arena by introducing an ad tier for its Prime Video service, scheduled to launch on January 29. This move, previously hinted at by the company last fall, integrates Prime Video with its comprehensive Prime subscription, encompassing various services like "free" delivery, Amazon Music, and more. With a minimal cost of $2.99 per month for Prime members to maintain an ad-free experience, the potential impact on Prime's annual service is expected to be negligible. Amazon assures that the commercials will be limited, aiming for significantly fewer ads than traditional TV and other streaming providers. For members who use the video service sparingly, the introduction of ads may go unnoticed, and Amazon cites the necessity to generate revenue for sustained investments in compelling content. The adoption of an advertising tier aligns with the industry trend, where most streaming services offer a budget-friendly option with ads. Even Netflix (NFLX), after years of resistance, has recently embraced the ad-tier model. Amazon, already incorporating ads in its Thursday Night Football broadcasts, focuses on adding ads to regular on-demand programming. Overall, this strategic move by Amazon to monetize its video streaming service is deemed wise, given the modest $2.99 monthly fee, likely prompting most users to choose an ad-free experience. Despite concerns about potential future price increases for Prime, currently priced attractively at $139 per year or $14.99 per month, the company's foray into the ad tier is perceived as a positive development for online ad platforms like TTD and MGNI. The stock's muted reaction is attributed to the anticipated nature of this news, which Amazon had hinted at months ago, and the additional factor of an FDA letter addressing potentially harmful pharmaceutical ingredients, possibly influencing the stock's performance.

Bristol Myers Squibb (BMY) has delivered a belated but significant holiday gift to RayzeBio (RYZB) investors by announcing its acquisition of RayzeBio for $62.50 per share in cash, totaling $4.1 billion in equity value, or $3.6 billion net of cash. This acquisition, resulting in a remarkable 104% premium over RayzeBio's closing price of $30.57 on Friday, has received unanimous approval from both companies' boards of directors and is anticipated to conclude in the first half of 2024. RayzeBio operates as a clinical-stage radiopharmaceutical therapeutics ("RPT") company with a primary focus on actinium-based RPTs and an ongoing pipeline of developmental programs. The allure for Bristol Myers Squibb lies in the potential of RPT technology to combat various cancerous tumors, particularly in solid tumors where more effective treatments are needed. RPTs work by binding to tumor cells and delivering targeted radiation to induce cancer cell death. Actinium-based RPTs, with their high potency and short firing range of the alpha-emitter, present advantages in terms of potential stronger efficacy and more targeted delivery compared to existing RPTs. Although RayzeBio has not commercially launched any products yet, its lead program, RYZ101, is in phase 3 development for treating gastroenteropancreatic neuroendocrine tumors and early-stage development for small cell lung cancer, among other potential tumor types. Despite the absence of an immediate financial boost for Bristol Myers Squibb, the company perceives the deal as fortifying its oncology portfolio and enhancing growth prospects in the latter half of the decade. Bristol Myers emphasizes that RPTs are already transforming cancer care, and RayzeBio is at the forefront of pioneering this novel modality. The acquisition aims to expedite RayzeBio's preclinical and clinical programs, and, in addition to gaining access to RPT technology, Bristol Myers will acquire a state-of-the-art manufacturing facility currently under construction in Indianapolis, with GMP drug production scheduled to commence in the first half of 2024. The significant premium paid by Bristol Myers, entirely in cash, underscores the perceived transformative potential of RayzeBio's RPT platform. Despite the $4 billion price tag not being colossal in comparison to Bristol Myers' $105 billion market cap, the cash transaction signals the strategic importance assigned to RayzeBio's technology. Beyond the premium, RayzeBio stands to benefit from the larger pharma company's deeper pockets, accelerating its development pipeline and creating opportunities with potential new customers, contingent on future approvals. As a notable side note, Fusion Pharma (FUSN), a clinical-stage oncology company focusing on radiopharmaceuticals as precision medicines, is trading higher in sympathy with this development.

Synopsys (SNPS), a provider of electronic design automation software for chip testing and design, experienced a sell-off in the final hour of Friday's session after a Wall Street Journal report hinted at the company's potential interest in acquiring Ansys (ANSS), a developer of engineering simulation software. Subsequent details of the rumored transaction emerged after Friday's close, with Reuters reporting that Ansys was fielding takeover offers exceeding $400 per share, representing a roughly 17% premium to Friday's opening price. Although no formal deal has been established, the outcome remains uncertain, as Ansys continues to trade below the speculated acquisition price. Reuters anticipates a formal announcement in the coming weeks. The strategic rationale behind a Synopsys/Ansys acquisition lies in Ansys' extensive experience in developing engineering simulation software, with a well-established competitive advantage spanning various industries. Ansys' simulation software entails significant training costs, creating a defensive revenue stream. While Ansys faced a revenue downturn in the last quarter, primarily due to additional export restrictions imposed by the U.S. Department of Commerce on certain Chinese businesses, this is perceived as a short-term challenge. Ansys boasts impressive margins, maintaining gross margins exceeding 90% in Q3, showcasing effective expense management by its leadership. However, this efficiency limits the potential for Synopsys to achieve substantial cost savings through expense reductions, thereby capping potential synergies. The rapid decline in Synopsys' shares following reports of a possible Ansys takeover can be attributed to concerns about the speculated high acquisition cost. Purchasing Ansys at $400 per share would result in valuation metrics such as 15x estimated FY23 revenue and 46x adjusted earnings, surpassing levels observed in several other software tech giants like ORCL, ADBE, and CRM. Investor backlash against the anticipated hefty price tag reflects apprehensions about the economic feasibility of such an acquisition. Despite Ansys' significant economic moat, shaped by its extensive industry history and high switching costs, its recent revenue decline in Q3, attributed to China restrictions, adds a layer of complexity. Nonetheless, the potential long-term benefits of integrating Ansys into Synopsys, particularly amid rising semiconductor content, make it a strategically sound move. The short-term fluctuations in stock prices provide potential entry points for investors, even as uncertainties loom.

In a pharmaceutical landscape marked by sluggish M&A activity, the healthcare sector has witnessed a surge in deal-making as companies with ample cash reserves seek to strengthen their drug portfolios. This trend was underscored by Bristol-Myers Squibb (BMY) in its recent announcement of the acquisition of Karuna Therapeutics (KRTX), a clinical-stage biotech company specializing in neurological disease treatments, for a substantial $14.0 billion. BMY's strategic move follows a string of notable healthcare deals, including Roche Holdings' $2.7 billion acquisition of Carmot Therapeutics on December 4 and AbbVie's purchases of Cerevel Therapeutics for $8.7 billion and ImmunoGen for $10 billion in December and November, respectively. This acquisition marks BMY's second in recent times, following its purchase of oncology company Mirati Therapeutics (MRTX) on October 9, aimed at bolstering its cancer treatment portfolio. However, the KRTX acquisition holds particular promise for BMY's neuroscience business. At the heart of this deal lies KarXT, a potential groundbreaking treatment for schizophrenia and Alzheimer's disease psychosis, anticipating FDA approval by September 26, 2024. KRTX reported positive Phase 3 data for KarXT in March, demonstrating a significant 8.4-point reduction in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo, a key milestone. The drug's tolerability and safety profile present a marked improvement over existing schizophrenia treatments, addressing serious side effects such as Parkinson's disease-like shaking, sedation, insomnia, and weight gain. By targeting different receptors (M1/M4 Muscarinic Receptors), KarXT aims to mitigate these adverse effects, as evidenced by clinical trial data. With an estimated 1.6 million people treated for schizophrenia in the U.S., KarXT, if approved, holds the potential to become a blockbuster, multi-billion-dollar drug for BMY. The offer price of $330 per share, a 53% premium from the previous day's closing price, reflects the company's confidence in the acquisition's strategic value. This move by BMY is noteworthy considering its existing growth challenges, particularly the decline in Revlimid sales by 41% to $1.4 billion and stagnant sales of Eliquis at $2.7 billion in Q3. Despite the expected dilution to EPS by approximately $0.30/share in 2024 due to financing costs, investors have responded positively, with BMY shares trading higher. This is a departure from the usual market trend, where acquiring companies often see a decline in their stock value on news of a buyout, especially if the deal is dilutive to earnings per share (EPS). Overall, the KRTX acquisition aligns with BMY's strategy to expand its neuroscience treatment portfolio and potentially offer a best-in-class solution for the challenging landscape of schizophrenia treatment.

Previous update:

In a landscape where overall merger and acquisition activity remains subdued, the pharmaceutical and biotech sectors are witnessing a surge in deal-making as cash-flush healthcare companies seek to enhance their drug portfolios. Bristol-Myers Squibb (BMY) exemplified this trend by announcing its $14.0 billion acquisition of Karuna Therapeutics (KRTX), a clinical-stage biotech firm specializing in neurological disease treatments. This move follows BMY's recent purchase of oncology company Mirati Therapeutics (MRTX) in October and aligns with a broader trend of robust deal-making in the healthcare sector, including high-profile acquisitions by Roche Holdings and AbbVie. The focal point of the acquisition is KarXT, a potential groundbreaking treatment for schizophrenia and Alzheimer's disease psychosis, anticipated to undergo FDA approval in September 2024. Karuna Therapeutics reported positive Phase 3 data for KarXT, demonstrating a significant reduction in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo. Notably, the drug exhibits a promising tolerability and safety profile, addressing a common issue with existing schizophrenia treatments—severe side effects leading to medication discontinuation. The acquisition of Karuna Therapeutics positions BMY to potentially capitalize on KarXT as a blockbuster drug, catering to the estimated 1.6 million people treated for schizophrenia in the U.S. alone. With the potential for approval in additional indications like Alzheimer's disease psychosis, the total addressable market expands significantly. Despite the hefty $330 per share offer price, representing a 53% premium, investors have responded positively, driving BMY shares higher. The strategic move comes at a time when BMY faces a growth slowdown, particularly with its chemotherapy treatment Revlimid encountering heightened competition from generics. In Q3, Revlimid sales experienced a 41% decline, prompting BMY to explore new avenues for growth. While the acquisition is expected to be dilutive to earnings per share (EPS) by approximately $0.30 in 2024, BMY's willingness to make this significant investment underscores its commitment to expanding its neuroscience treatment portfolio and addressing the challenges associated with treating schizophrenia.

NIKE (NKE) is experiencing a notable downturn as its second-quarter (2Q24) earnings report falls short of expectations, casting doubt on the sports and athletic footwear giant's market dominance. Anticipation for improved margins and a brighter growth outlook was met with a mixed outcome. The company achieved gross margin expansion of 170 basis points year-on-year and 40 basis points sequentially, reaching 44.6%, attributed to inventory reduction efforts supporting stronger pricing. Despite navigating a highly promotional retail environment, NKE projects further gross margin expansion in Q3 (160-180 basis points) and Q4 (225-250 basis points). In tandem with cost containment measures, specifically a mere 1% increase in SG&A costs to $4.1 billion, NKE surpassed earnings expectations, with earnings per share (EPS) growing 21% year-on-year to $1.03. However, this positive news is overshadowed by sluggish sales in Q2 and a less optimistic sales outlook. North America witnessed a 4% revenue decline, with wholesale revenues down 2%, contrasting with the optimistic sentiment following strong reports from Dick's Sporting Goods and Foot Locker. Greater China's growth decelerated to 8%, raising concerns about NKE losing ground to competitors like lululemon. Despite solid demand during peak shopping periods, NKE faced relative weakness in business outside these peak days, particularly in its digital platforms, where lower-than-expected traffic was observed amid heightened promotional activities by competitors. The outlook for the next few quarters remains dim, leading to a downward revision of NKE's FY24 revenue growth forecast to approximately 1%, down from the previous mid-single-digit estimate. This performance prompts concerns that NKE might be ceding ground to competitors and losing its competitive edge. CEO John Donahoe recognizes the need to accelerate innovation and announces a multi-year product innovation cycle, introducing new franchises and platforms in the coming years. To finance these initiatives, NKE is implementing a $2 billion cost-savings plan centered on automation, technology use, streamlining efforts, and simplifying the product assortment. The key takeaway is that NKE's disappointing Q2 sales and 2H24 outlook raise concerns beyond macroeconomic factors, suggesting a potential loss of edge in product innovation, contributing to the current substantial selloff.

AAR Corp. (AIR) experiences a slight downturn following its Q2 (Nov) earnings report, signaling a dip in altitude despite positive prospects for calendar year 2024. This aviation services provider, catering to both commercial and defense aircraft, encountered a modest earnings beat, with a smaller upside compared to recent quarters. The focal point of concern lies in the top-line results, as revenue increased by 16.1% year-on-year to $545.4 million but fell short of analyst expectations. Sales to commercial customers, constituting 71% of total sales in Q2, rose impressively by 24% year-on-year, driven by robust demand for new and used parts. Conversely, government sales only increased by 1%. Within its business segments, the Parts Supply category saw a 24% increase in sales, fueled by strong demand for used serviceable material and expansion in commercial distribution activities. Repair & Engineering reported an 8% sales increase, attributed to strong performance in hangars and component repair operations, while Integrated Solutions experienced a 23% sales uptick due to increased flight hours. However, the Expeditionary Services segment faced challenges, with sales declining by 34% due to reduced mobility shipments of pallets to the Department of Defense, a consequence of diverted funding to the effort in Ukraine. Despite these challenges, there are positive indicators, such as the adjusted operating margin rising to 8.1%, driven by growth in commercial sales. Although AIR doesn't provide specific guidance, it notes a robust macro environment in the commercial aviation aftermarket, with customers expressing strong demand for services in calendar year 2024. Continued constraints on new aircraft deliveries and issues related to newer generation engines are anticipated to enhance demand for mid-to-late life aircraft, a core market for AIR. While the chart reflects an impressive trajectory for AIR, echoing Boeing's significant move since late October, the recent Fed announcement signaling a slowdown in rate hikes has been a key catalyst. The prevalence of bullish sentiment leading up to the Q2 report resulted in a slightly negative surprise with a modest EPS beat and a revenue miss. However, the outlook for calendar year 2024 appears promising.

Previous update:

Apogee Enterprises (APOG) reported a solid performance in Q3, achieving its ninth consecutive earnings beat with double-digit growth. Despite falling short on revenue expectations and revising down its FY24 revenue growth forecast, the company's focus on margin improvement showcased positive outcomes. Notably, APOG's cost-saving initiatives yielded impressive results, with gross margins expanding by 310 basis points to 26.6% and operating margins rising to 11.1%, surpassing the long-term target of 10%. This success prompted an upward revision of APOG's FY24 adjusted EPS guidance to $4.55-4.70 from $4.35-4.65. Architectural Glass played a significant role in driving Q3 performance, contributing to an 11.6% YoY increase in net sales to $91.0 million and supporting robust operating margins. However, Architectural Framing Systems and Architectural Services faced volume pressures, resulting in a 15.4% and 7.2% decline in net sales to $139.6 million and $94.7 million, respectively. This led to an overall 7.7% YoY drop in revenue to $339.7 million, missing estimates. The subdued volumes were attributed to ongoing uncertainties in the construction markets, where non-residential construction exhibited growth primarily driven by manufacturing projects, an area where APOG has limited participation. While APOG acknowledged the challenges posed by macroeconomic factors such as higher interest rates, tighter lending standards, and cost inflation, it remained optimistic about low single-digit growth rates in commercial construction for 2024. Despite the cautious outlook, APOG highlighted institutional and infrastructure projects benefiting from government funding, and the recent Federal Reserve signal of an interest rate pause could mitigate the impact on commercial construction, potentially leading to a shallower downturn. The company sees M&A opportunities emerging in a more favorable market, indicating a positive stance. While facing economic disruptions in 2024, APOG's strategic shift towards higher-margin segments positions it well to navigate challenges, especially if interest rates undergo a more significant decline.

Paychex (PAYX) faces a setback as slowing job growth impacts its outlook, resulting in a decline in its performance following Q2 results. Despite last quarter's optimism regarding potential FY24 revenue growth, PAYX now anticipates growth to fall within the initially forecasted 6-7% range. While Q2 showed resilience, with PAYX surpassing EPS and revenue estimates due to sustained demand from small and medium-sized businesses (SMBs), the subsequent quarter presented challenges. CEO John Gibson highlighted a moderation in job growth and wage inflation among small businesses, and observed softening in large client business segments, including HR outsourcing. Despite these challenges, PAYX experienced relative strength in various sectors, such as Professional Employer Organization (PEO), mid-market, human capital management (HCM), and retirement. 1H24 revenue growth in these areas reached 6%, propelled by new client acquisitions across PAYX's suite of HCM offerings and an uptick in PEO worksite employees. Although the macroeconomic backdrop poses challenges to job growth, companies are reassessing HR and benefits strategies due to the tight labor market and escalating healthcare costs. While PAYX's 6% top-line growth may seem moderate, the company's steady business performance remains an appealing quality. Revenue retention surpasses pre-pandemic levels, with record-high retention in the HR outsourcing solutions business. Despite external macroeconomic factors influencing a minor regression from the previous quarter, PAYX continues to exhibit earnings growth, with a 9% year-over-year increase in EPS. The Q3 operating margin guidance of 44-45% reflects expansion from the 40.2% achieved in Q2. However, significant upward movement in the stock is contingent on notable improvements in the labor market conditions, posing a challenge in the current scenario.

Carnival (CCL) is experiencing a surge in its stock value today after releasing its Q4 (Nov) earnings report, showcasing robust earnings and optimistic commentary on bookings. The cruise line reported a substantial 40.6% year-over-year increase in revenue, reaching a Q4 record of $5.40 billion, surpassing expectations. Despite this positive performance, CCL provided guidance for Q1 with an adjusted loss of approximately $(0.22), falling short of analyst predictions. The company also offered FY24 adjusted EPS guidance that was below analyst expectations. In evaluating the financials, adjusted EBITDA, a relevant metric for capital-intensive cruise ships, exceeded expectations at $946 million in Q4, surpassing prior guidance of $800-900 million and significantly outperforming the $(96) million loss from the previous year. Q1 adjusted EBITDA guidance stands at approximately $800 million, and for FY24, it is projected to be around $5.6 billion. Carnival highlighted its strong finish to FY23, achieving another record-breaking quarter and consistent outperformance throughout the year due to heightened demand across all brands. Q4 net yields exceeded those of a robust 2019, surpassing CCL's expectations. Regarding bookings, CCL entered FY24 with an unprecedented booked position, with nearly two-thirds of its occupancy already reserved for 2024 at substantially higher prices in constant currency. Notably, booking volumes during Q4 remained significantly elevated, surpassing both the prior year and 2019 comparable periods. Black Friday and Cyber Monday also saw record-breaking booking volumes, while European brands exhibited remarkable strength with double-digit booking volumes at considerably higher prices. In summary, Carnival's Q4 performance was solid, marked by positive results and strong demand, pricing, and bookings. Particularly noteworthy is CCL's assertion that its booked position for 2024 is the strongest ever recorded. Despite providing guidance below expectations, investors seem less affected, possibly anticipating conservative guidance from CCL, which is a characteristic of the company.

Cintas (CTAS) is experiencing a significant uptick in its stock value following the release of robust Q2 (Nov) results this morning. After a narrower beat in Q1, Cintas has returned to its customary double-digit EPS beat in Q2, coupled with favorable revenue performance. Notably, the highlight of the quarter was Cintas once again raising its FY24 EPS and revenue outlook by a margin surpassing the Q2 upside, signaling optimism for Q3-Q4. This pattern of upward adjustments in both Q1 and Q2 suggests management's confidence in the company's outlook for the second half of the fiscal year. Cintas serves as a valuable indicator of businesses' near-term prospects, renowned as the largest provider of work uniforms in the U.S. Additionally, it derives over half of its revenue from facility services encompassing cleaning supplies, mops, first aid cabinets, PPE, fire extinguishers, and alarms. The Uniform Rental and Facility Services segment, the larger of the two, witnessed an 8.2% year-over-year increase in revenue to $1.85 billion. Other revenue, with a substantial contribution from its First Aid segment, rose by 13.3% year-over-year to $526.6 million. Margins emerged as a positive aspect in Q2, with gross margin improving to 48.0% from the previous year's 47.0%, driven by robust volume growth and sustained operational efficiencies. Despite facing lower energy expenses, specifically in gasoline, natural gas, and electricity, by 40 basis points year-over-year, Cintas, heavily reliant on truck deliveries for uniforms, demonstrated resilience to external factors like fluctuating gas prices. Moreover, operational efficiency improvements were evident as the operating margin increased to 21.0% from 20.5% year-over-year, despite increased investments in selling resources, technology, and the management trainee program. Regarding EPS guidance, Cintas substantially increased its FY24 outlook to $14.35-14.65 from the previous $14.00-14.45, a move that could have been more conservative considering the remaining half of the fiscal year. The decision to raise FY24 projections by an amount exceeding the Q2 beat implies optimism for the second half, contributing to the stock's notable surge. In summary, Cintas impressively rebounded to report double-digit EPS beats after a narrow beat in Q1. The company's success can be attributed to robust volumes, leading to improved margins and operational efficiencies. Overall, Cintas remains a favorable choice with a consistent and predictable business model featuring a robust recurring revenue component. Additionally, the company benefits from the broader trend of businesses outsourcing functions to focus on their core operations.

Micron (MU) is experiencing a notable turnaround, with the challenging inventory situation in the data center, PC, and smartphone markets showing signs of improvement. The company, along with other chip makers, has faced difficulties due to elevated inventory levels, but the latest earnings report for Q1 indicates a positive shift. Improved demand is contributing to higher DRAM/NAND prices, leading to an upside in earnings. Micron's optimistic outlook extends to Q2, with the company guiding EPS, revenue, and gross margin above expectations, while expressing confidence in its prospects for FY24 and FY25. The recovery in the PC market, emphasized by semiconductor companies like Intel (INTC) and Advanced Micro Devices (AMD), is a key factor benefiting Micron. The healthier PC market, with demand from OEMs aligning closely with end-market demand, has positively impacted Micron's performance. Looking ahead, Micron foresees continued momentum, anticipating low-to-mid single-digit growth in PC unit volume for 2024 after experiencing double-digit declines in the past two years. A significant aspect of Micron's success lies in the data center end market, where GPU-enabled AI servers are gaining traction. These advanced servers, featuring higher bandwidth memory capacity and enhanced performance requirements, are addressed by Micron's new HBM3E chipset. Samples of HBM3E, shipped in Q1, are in the final qualification stages for use in NVIDIA's (NVDA) Grace Hopper GH200 and H200 platforms. In 2024, Micron expects to generate "several hundred million" dollars in HBM3E revenue as volume production ramps up, with growth accelerating into 2025. As the supply-demand imbalance levels out and generative AI becomes more integrated into PCs and smartphones with on-device capabilities, Micron anticipates continued improvement in pricing dynamics for DRAM and NAND in FY24. In Q1, the non-GAAP gross margin turned positive at 0.8%, surpassing previous guidance and demonstrating a significant improvement from the previous quarter. Q2 is expected to witness further expansion, with Micron guiding for a non-GAAP gross margin of 13.0%, +/- 1.5%. Micron's impressive Q1 earnings report, marked by a beat-and-raise scenario, indicates a transition from a downturn to a recovery in the memory space, with prospects of growth in FY24. Looking ahead to FY25, Micron envisions a record total addressable market as AI applications proliferate across the data center, PC, and smartphone markets.